Etomidate

Etomidate

Form: Intravenous (IV) Injection/Emulsion

Strength: 2 mg/mL

Reference Brands: Amidate(US); Etomidate-Lipuro(EU)

Category: Critical Care

Etomidate is a rapid-onset intravenous anesthetic agent used primarily for the induction of general anesthesia and rapid sequence intubation (RSI), particularly in hemodynamically unstable patients. It is available as a 2 mg/mL solution in 10 mL and 20 mL vials, ampoules, or pre-filled syringes. In the US, Etomidate is marketed under the brand name Amidate by Pfizer, along with generics from Baxter, Hikma, and others. In the EU, Etomidate-Lipuro by B. Braun and Hameln brands are widely distributed. Etomidate is a critical care medication supplied through pharma B2B platforms to hospitals, emergency units, and surgical centers worldwide.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.